Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetes

Abstract Aims/Introduction Ultra‐rapid lispro (URLi) is a novel ultra‐rapid mealtime insulin. This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog®) in Japanese patients with type 1 diabetes mellitus. Materials and Methods This was a...

Full description

Bibliographic Details
Main Authors: Masanari Shiramoto, Risa Nasu, Tomonori Oura, Makoto Imori, Kenji Ohwaki
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Journal of Diabetes Investigation
Subjects:
Online Access:https://doi.org/10.1111/jdi.13195